Work

Engineered T cell therapy for the treatment of cardiac fibrosis during chronic phase of myocarditis

Year: 2025

Type: article

Abstract: : FAP.CAR-T cells eliminate fibrosis-driving myofibroblasts, reversing cardiac dysfunction in chronic myocarditis. This strategy, validated in human organoids, offers translatable immunotherapy for fibrosis-driven heart disease.

Source: Theranostics

DOI: 10.7150/thno.116749

Authors: Xiumeng Hua, Zhe Sun, Ziwei Liang, Yanhong Huang, Han Mo, Fei Dong, Shimin Mo, Xingyue Yang, Ningning Zhang, Xiao Chen, Shumin Liao, Zhen Qi, Rosanna Zhang, Shuge Guan, Liang Li, Yang Xu, Jiangping Song

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Fu Wai Hospital, State Key Laboratory of Cardiovascular Disease, Southern University of Science and Technology, Kunming Medical University, Fuwai Yunnan Cardiovascular Hospital

Language: English

Topic: Cardiac Fibrosis and Remodeling

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,671

OpenAlex ID: W4417068296

FWCI: 0.635

Cites:

Cited by: 1

Related to: